Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease
Helios Pareja-Galeano, Alejandro Santos-Lozano, María Morán
1Research Institute of Hospital 12 de Octubre (i+12), 6th Floor, Laboratories Sector, CAA Building, Avda. de Córdoba s/n, 28041 Madrid, Spain. fabian.sanchis@uv.es.
Abstract:
The intent of this article is to summarize current body of knowledge on the potential implication of the xanthine oxidase pathway (XO) on skeletal muscle damage. The possible involvement of the XO pathway in muscle damage is exemplified by the role of XO inhibitors (e.g., allopurinol) in attenuating muscle damage. Reliance on this pathway (as well as on the purine nucleotide cycle) could be exacerbated in conditions of low muscle glycogen availability. Thus, we also summarize current hypotheses on the etiology of both baseline and exertional muscle damage in McArdle disease, a condition caused by inherited deficiency of myophosphorylase. Because myophosphorylase catalyzes the first step of muscle glycogen breakdown, patients are unable to obtain energy from their muscle glycogen stores. Finally, we provide preliminary data from our laboratory on the potential implication of the XO pathway in the muscle damage that is commonly experienced by these patients.
Insights
The xanthine oxidase (XO) pathway may contribute to skeletal muscle damage, particularly when muscle glycogen is low, as seen in McArdle disease. XO inhibitors show potential in reducing this damage.
Area of Science:
- Biochemistry
- Exercise Physiology
- Muscle Metabolism
Background:
- The xanthine oxidase (XO) pathway is implicated in cellular damage.
- Skeletal muscle damage can occur due to various factors, including metabolic disturbances.
- McArdle disease presents a unique model of impaired muscle glycogenolysis.
Purpose of the Study:
- To review the role of the xanthine oxidase pathway in skeletal muscle damage.
- To explore the connection between XO, purine metabolism, and muscle injury under glycogen-depleted conditions.
- To present preliminary data on XO's involvement in McArdle disease-related muscle damage.
Main Methods:
- Literature review on xanthine oxidase and muscle damage.
- Hypothesis formulation regarding purine nucleotide cycle and glycogen availability.
- Presentation of preliminary laboratory data.
Main Results:
- Xanthine oxidase inhibitors like allopurinol may attenuate muscle damage.
- Impaired muscle glycogen availability may increase reliance on the XO pathway.
- Preliminary data suggest a potential role for XO in McArdle disease muscle damage.
Conclusions:
- The xanthine oxidase pathway is a potential contributor to skeletal muscle damage.
- Further research is warranted to elucidate the precise mechanisms and therapeutic potential of targeting XO in muscle injury, especially in metabolic myopathies.
Related Concept Videos
Muscle Recovery and Fatigue
Electron Transport Chain: Complex III and IV
Myocarditis I: Introduction
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Satellite Stem Cells and Muscular Dystrophy


